Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial

Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial

INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of...

Full description

Saved in:
Bibliographic Details
Main Authors: Siyue Jia, Chengwei Shao, Xin Cheng, Hongxing Pan, Zhijian Wang, Yu Xia, Jianfang Xu, Xuefen Huai, Danjing Leng, Jiarong Wang, Gan Zhao, Bin Wang, Jingxin Li, Fengcai Zhu
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
COVID-19
DNA vaccine
immunogenicity
safety
primary immunization
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2448405
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items